Skip to content

Agilent Technologies A Equity Method Investments

Equity Method Investments at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$23.7M+3.0%
Bruker logo
BrukerBRKR
Illumina logo
IlluminaILMN

Other financials

Income statement

See full
Revenue$1.8B+10.0%
Gross profit$990.0M+14.3%
Operating income$399.0M+33.0%
Net income$339.0M+57.7%
EPS (diluted)$1.20+60.0%

Balance sheet

See full
Cash & equivalents$1.8B+21.5%
Total debt$3.5B-3.9%
Total equity$7.1B+16.1%
Total assets$13.1B+7.5%

Cash flow

See full
Operating cash flow$277.0M+25.3%
CapEx$76.0M-33.3%
Free cash flow$201.0M+87.9%

Valuation

See full
Market cap$39.14B+15.3%
Enterprise value$40.87B+13.0%
P/E27.7×-1.4×
P/S5.4×+0.3×

Profitability

See full
Gross margin52.7%-0.6pp
Operating margin21.5%+0.1pp
Net margin19.6%+2.0pp
FCF margin15%-2.9pp

Returns & leverage

See full
Return on equity21.3%+2.4pp
Debt / equity0.5×-0.1×
Current ratio2.1×0.0×

Where this comes from

Reported directly by Agilent Technologies in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Agilent Technologies’s 10-Q, filed June 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agilent Technologies's equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agilent Technologies's equity method investments?
Agilent Technologies (A) reported equity method investments of $54M in Q1 2026.
How has Agilent Technologies's equity method investments changed year-over-year?
Agilent Technologies's equity method investments decreased by 11.5% year-over-year, from $61M to $54M.
What is the long-term trend for Agilent Technologies's equity method investments?
Over 5 years (2020 to 2025), Agilent Technologies's equity method investments has grown at a 5.2% compound annual growth rate (CAGR), from $103M to $133M.
What does equity method investments mean?
Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.